Martin and colleagues’ latest study, published in June 2024 in JAMA Health Forum, finds that the Vot-ER project reaches a younger and more racially and ethnically diverse population, groups that are ...
The FDA grants rare pediatric disease designation for serious or life-threatening diseases that affect fewer than 200,000 people in the United States when those people are primarily younger than 18 ...
Nivolumab plus AVD “should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin’s lymphoma,” according to researchers.